Current guidelines to diagnosis pulmonary embolism in pregnant patients offer conflicting recommendations.
A French working group developed a treatment algorithm for diagnosis and treatment of neonatal thrombocytopenia of suspected or confirmed alloimmune origin.
Significantly fewer patients receiving apixaban experienced thromboembolism and major bleeding compared with patients receiving placebo.
An analysis of 2300 patients found similar prevalence of abdominal, pelvic, and thoracic cancer in patients with deep vein thrombosis and pulmonary embolism.
Patients receiving rivaroxaban did not experience a statistically significant decrease in thrombotic events compared with patients receiving placebo.
Researchers assessed potential risk factors for venous thromboembolism during pregnancy and postpartum in more than 100,000 Japanese women.
Antifactor Xa activity after heparin spiking was lower in plasma samples from antithrombin-deficient patients compared with control samples.
First FDA-approved therapy specifically indicated for the treatment of aTTP
Researchers assessed the prevalence of various antiphosphatidylserine/prothrombin antibodies in patients with primary antiphospholipid syndrome.
Researchers attempted to identify the appropriate platelet count transfusion threshold in preterm infants with severe thrombocytopenia.
The interactions between von Willebrand factors and its cleaving protease ADAMTS-13 recently emerged as risk factors for pediatric thromboembolism.
Statins may provide a therapeutic alternative to anticoagulant prophylaxis for venous thromboembolism.
The HERCULES (NCT02553317) study included 145 patients with aTTP who were randomized to receive either caplacizumab 10mg or placebo in conjunction with plasma exchange and immunosuppression.
Researchers conducted a systematic literature review to characterize the complications experienced by patients with upper extremity deep vein thrombosis.
Changes in health-related quality of life in patients with persistent/chronic immune thrombocytopenia were evaluated using 4 different tools.
No differences were observed in patency rates or incidence of post-thrombotic syndrome in patients treated with rivaroxaban or a vitamin K antagonist.
Compared with warfarin, rivaroxaban was found to reduce the risk of overall, gastrointestinal, and intracranial bleeding.
Women with breast cancer were found to experience increased risk of developing VTE.
Researchers analyzed 1915 patients with splanchnic vein thrombosis for risk of bleeding and arterial cardiovascular events.
A retrospective review uncovered significantly decreased OS and MFFS in patients with essential thrombocythemia after the approval of anagrelide.
The role of H Pylori in the development of immune thrombocytopenic purpura is still unclear.
Researchers performed a retrospective review of 1279 patients treated with a standardized, weight-adjusted tinzaparin regimen.
Bleeding scores improved in over half of the patients receiving cryopreserved platelets.
Researchers evaluated 12 studies including 4720 patients for recurrent VTE risk and major bleeding.
Prophylactic rituximab may decrease relapse in immune thrombotic thrombocytopenic purpura by maintaining detectable levels of ADAMTS13 activity.
Patients with pregnancy-onset ITP were more likely to deliver babies with neonatal thrombocytopenia compared with patients diagnosed before pregnancy.
Patients with VTE with moderate to severe thrombocytopenia at baseline were associated with increased risk for major bleeding events and all-cause mortality.
Results of the retrospective study require further confirmation.
Behçet disease should be considered an initial causative factor of cerebral venous sinus thrombosis.
Researchers investigated the characteristics and outcomes of patients with systemic lupus erythematosus-associated thrombotic microangiopathy based on their ADAMTS13 inhibitor profiles.
The aPS/PT antibodies might represent markers of aPL-related pregnancy complications, such as intrauterine grown restriction and preeclampsia.
A number of risk factors were associated with chronic thromboembolic pulmonary hypertension, including, age >70 years, female gender, and pulmonary embolism at first venous thromboembolism.
The efficacy of rituximab plus prednisolone had not been evaluated prior to the current study.
Recent data from EULAR 2018 highlight the existence of thrombotic factors in systemic lupus erythematosus.
At the end of 6 months, the rate of VTE recurrence was 4% among rivaroxaban patients vs 11% in the dalteparin arm (hazard ratio [HR] 0.43, 95% CI: 0.19 to 0.99).
A protocolized study including initiation of VA-ECMO may reduce mortality in patients with massive PE.
Researchers evaluated the prevalence, risk factors, and effect of venous thromboembolism on survival in systemic sclerosis.
D-dimer test adjustment based on pretest probability results may be a safe option to reduce the need for imaging during evaluation for pulmonary embolism.
Copeptin may be useful for identifying normotensive patients with pulmonary embolism who have a higher risk for an adverse outcome.
The Society of Radiologists in Ultrasound has endorsed recommendations regarding ultrasound imaging test protocols for patients with suspected deep venous thrombosis.
The US FDA granted approval to fostamatinib (Tavalisse), a kinase inhibitor, for the treatment of thrombocytopenia in patients with chronic IPT who have had an insufficient response to a previous treatment.
Observation in the emergency department followed by outpatient management with anticoagulation may be appropriate treatment for some patients with low-risk pulmonary embolism.
In patients at very low risk for pulmonary embolism, the pulmonary embolism rule-out criteria was noninferior to the conventional strategy of identifying thromboembolic events.
In patients with primary antiphospholipid syndrome, the presence of phosphatidylserine/prothrombin complex antibodies is associated with Raynaud phenomenon and migraine.
Certain risk scores may not be reliable for predicting the presence of a pulmonary embolism in pregnant or postpartum women.
In this prospective study, researchers sought to compare the effectiveness of IV methylprednisolone vs oral prednisone in hospitalized patients with newly diagnosed ITP.
Previous studies showed that there may be an association between ITP and CVD — especially among those who undergo splenectomy — but evidence is conflicting.
A clinical trial is underway to assess the safety and efficacy of dabigatran in intermediate-risk pulmonary embolism after completing 72 hours of heparin therapy.
Platinum-based chemotherapy agents for lung cancer may increase the risk for thromboembolism.
In this randomized trial, investigators sought to determine the effectiveness of high-dose dexamethasone vs conventional prednisone therapy in treatment-naïve patients with ITP. Results were presented at ASH 2017.
Nearly 13% of patients in the edoxaban had first recurrent VTE or other major bleeding events during the 12-month follow-up compared with 13.5% of patients in the dalteparin arm.